Akorn and CSL sign Aflurina distribution deal

USA-based drugmaker Akorn and CSL Biotherapies, the US subsidiary of Australia's CSL group, have entered into a specialty distributor agreement covering the sale of the latter's seasonal influenza vaccine Aflurina. Under the deal, financial terms of which were not disclosed, Akorn will market and distribute two presentations of the product: pre-filled syringes without latex or thimerosal; and preserved multi-dose vials.

Akorn's chief executive, Arthur Przybyl, said that Aflurina, the second such product in its portfolio after its tetanus/diptheria vaccine, would allow the firm to make the best use of its sales capabilities and existing vaccination expertise.